biological source
rabbit
Quality Level
conjugate
unconjugated
antibody form
serum
antibody product type
primary antibodies
clone
polyclonal
species reactivity
human
manufacturer/tradename
Chemicon®
technique(s)
immunohistochemistry: suitable, immunoprecipitation (IP): suitable, western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... BIRC5(332)
General description
Apoptosis is triggered by a variety of stimuli, including members of the Tumor Necrosis Factor (TNF) family, and prevented by the inhibitor of apoptosis (IAP) proteins. IAP proteins form a conserved gene family that binds to and inhibits cell death proteases. One of these IAP proteins, Survivin/TIAP, interacts with the processed form of caspase-3 and has been shown to inhibit its proteolytic activity. Survivin/TIAP is predominantly expressed in tissues of embryos, transformed cell lines, and many human cancers and lymphomas.
Immunogen
Recombinant, GST-tagged full length human Survivin
Application
Immunoblotting: Recommended antibody dilution 1:3000-6000
Immunoprecipitation: Recommended antibody dilution 1:200
Immunohistochemisty: Recommended antibody dilution 1:1500
Optimal antibody dilutions must be determined by end-user.
Immunoprecipitation: Recommended antibody dilution 1:200
Immunohistochemisty: Recommended antibody dilution 1:1500
Optimal antibody dilutions must be determined by end-user.
This Anti-Survivin Antibody is validated for use in WB, IP, IH for the detection of Survivin.
Physical form
Serum with no preservatives
Preparation Note
Maintain at -20°C for up to 6 months after date of receipt.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
存储类别
10 - Combustible liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Inhibition of IL-6 expression in LNCaP prostate cancer cells by a combination of atorvastatin and celecoxib.
Wang, H; Cui, XX; Goodin, S; Ding, N; Van Doren, J; Du, Z; Huang, MT; Liu, Y; Cheng et al.
Oncology Reports null
Linfei Hu et al.
Cell death & disease, 13(2), 124-124 (2022-02-10)
The use of the BRAF inhibitor vemurafenib exhibits drug resistance in the treatment of thyroid cancer (TC), and finding more effective multitarget combination therapies may be an important solution. In the present study, we found strong correlations between Ref-1 high
Oral Free Paper Sessions.
Virchows Archiv : an international journal of pathology, 469 Suppl 1, 1-346 (2016-08-25)
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| AB3610 | 04053252280184 |